Chronic kidney disease increases risk for venous thromboembolism

Journal of the American Society of Nephrology

Volumn 19, Issue 1, 2008, Pages 135-140

  Wattanakit, Keattiyoat ^a   Cushman, Mary ^b   Stehman Breen, Catherine ^c,d   Heckbert, Susan R ^d   Folsom, Aaron R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMMUNITY CARE; CONFIDENCE INTERVAL; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; POPULATION RISK; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 38149017626     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007030308     Document Type: Article

References (26)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151: 933-938, 1991
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 158: 585-593, 1998
3. Hansson PO, Welin L, Tibblin G, Eriksson H: Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913.' Arch Intern Med 157: 1665-1670, 1997
4. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR: Deep vein thrombosis and pulmonary embolism in two cohorts: The Longitudinal Investigation of Thromboembolism Etiology. Am J Med 117: 19-25, 2004
5. Anderson FA Jr, Spencer FA: Risk factors for venous thromboembolism. Circulation 107: 19-116, 2003
6. Wiesholzer M, Kitzwogerer M, Harm F, Barbieri G, Hauser AC, Pribasnig A, Bankl H, Balcke P: Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 33: 702-708, 1999
7. Stein PD, Henry JW: Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108: 978-981, 1995
8. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39: 1011-1017, 2002
9. Abbott KC, Cruess DF, Agodoa LY, Sawyers ES, Tveit DP: Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States. Am J Kidney Dis 43: 120-130, 2004
10. The PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 263: 2753-2759, 1990
11. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126[Suppl]: 338S-400S, 2004
12. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 108: 312S-334S, 1995
13. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793-800, 1999
14. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110: 874-879, 2004
15. Machleidt C, Mettang T, Stärz E, Weber J, Risler T, Kuhlmann U: Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int 36: 1119-1124, 1989
16. Oger E, Lacut K, Van Dreden P, Bressollette L, Abgrall JF, Blouch MT, Scarabin PY, Mottier D: High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica 88: 465-469, 2003
17. Rydzewski A, Mysliwiec M, Soszka J: Concentration of three thrombin inhibitors in the nephrotic syndrome. Nephron 4: 200-203, 1986
18. Singhal R, Brimble KS: Thromboembolic complications in the nephritic syndrome: Pathophysiology and clinical management. Thromb Res 118: 397-407, 2006
19. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
20. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41: 264-270, 1995
21. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70: 380-385, 1993
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
23. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920-929, 2002
24. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004
25. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A: Cystatin C: Efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 20: 97-102, 2000
26. Erlandsen EJ, Randers E, Kristensen JH: Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 59: 1-8, 1999